Revolution Medicines
Patents, Design & Utilities

Last updated:

List of all Revolution Medicines patents 34 in total

Status Patent
Application
Utility: COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF External link
Filling date: 6 Sep 2025 Issue date: 12 May 2022
Application
Utility: COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF External link
Filling date: 6 Sep 2025 Issue date: 12 May 2022
Application
Utility: BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF External link
Filling date: 6 Sep 2025 Issue date: 5 May 2022
Application
Utility: RAS INHIBITORS External link
Filling date: 6 Sep 2025 Issue date: 7 Apr 2022
Application
Utility: IDENTIFYING NEW THERAPEUTIC AGENTS External link
Filling date: 6 Sep 2025 Issue date: 17 Mar 2022
Application
Utility: SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER External link
Filling date: 6 Sep 2025 Issue date: 3 Feb 2022
Grant
Utility: Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2- -oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor External link
Filling date: 6 Sep 2025 Issue date: 11 Jan 2022
Application
Utility: METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES External link
Filling date: 6 Sep 2025 Issue date: 30 Dec 2021
Grant
Utility: Bicyclic heteroaryl compounds and uses thereof External link
Filling date: 6 Sep 2025 Issue date: 9 Nov 2021
Application
Utility: C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors External link
Filling date: 6 Sep 2025 Issue date: 4 Nov 2021
Application
Utility: METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES External link
Filling date: 6 Sep 2025 Issue date: 16 Sep 2021
Application
Utility: SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2- -OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR External link
Filling date: 6 Sep 2025 Issue date: 19 Aug 2021
Grant
Utility: Compounds that participate in cooperative binding and uses thereof External link
Filling date: 6 Sep 2025 Issue date: 13 Jul 2021
Application
Utility: SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER External link
Filling date: 6 Sep 2025 Issue date: 27 May 2021
Application
Utility: BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF External link
Filling date: 6 Sep 2025 Issue date: 13 May 2021
Application
Utility: RAS INHIBITORS External link
Filling date: 6 Sep 2025 Issue date: 6 May 2021
Application
Utility: RAS INHIBITORS External link
Filling date: 6 Sep 2025 Issue date: 6 May 2021
Application
Utility: RAS INHIBITORS External link
Filling date: 6 Sep 2025 Issue date: 6 May 2021
Grant
Utility: Identifying new therapeutic agents External link
Filling date: 6 Sep 2025 Issue date: 27 Apr 2021
Grant
Utility: C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors External link
Filling date: 6 Sep 2025 Issue date: 20 Apr 2021
Application
Utility: 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS External link
Filling date: 6 Sep 2025 Issue date: 8 Apr 2021
Application
Utility: RAPAMYCIN ANALOGS AS MTOR INHIBITORS External link
Filling date: 6 Sep 2025 Issue date: 1 Apr 2021
Grant
Utility: Methods and reagents for analyzing protein-protein interfaces External link
Filling date: 6 Sep 2025 Issue date: 16 Mar 2021
Application
Utility: POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS External link
Filling date: 6 Sep 2025 Issue date: 31 Dec 2020
Application
Utility: SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER External link
Filling date: 6 Sep 2025 Issue date: 26 Nov 2020
Application
Utility: COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF External link
Filling date: 6 Sep 2025 Issue date: 5 Nov 2020
Application
Utility: PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS External link
Filling date: 6 Sep 2025 Issue date: 29 Oct 2020
Application
Utility: COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF External link
Filling date: 6 Sep 2025 Issue date: 25 Jun 2020
Application
Utility: COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF External link
Filling date: 6 Sep 2025 Issue date: 25 Jun 2020
Grant
Utility: 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors External link
Filling date: 6 Sep 2025 Issue date: 17 Mar 2020
Application
Utility: PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS External link
Filling date: 6 Sep 2025 Issue date: 16 Jan 2020
Application
Utility: BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS External link
Filling date: 6 Sep 2025 Issue date: 16 Jan 2020
Grant
Utility: Compounds that participate in cooperative binding and uses thereof External link
Filling date: 6 Sep 2025 Issue date: 14 Jan 2020
Application
Utility: C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors External link
Filling date: 6 Sep 2025 Issue date: 7 Nov 2019

Showing 1 to 34 of 34 patents.